Supernus Pharmaceuticals, Inc. (SUPN): Net Income
-$38.55M
Year ended 2025-12-31
-$109.89M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$38.55M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $73.86M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $1.32M | -97.8% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $60.71M | +13.6% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $53.42M | -57.9% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $126.95M | +12.3% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $113.06M | +1.9% | 2022-04-13, From 2019-01-01 |
| 2018-12-31 | $110.99M | +93.8% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $57.28M | -37.2% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $91.22M | +554.2% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $13.94M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$10.93M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$92.27M | n/m | 2017-01-20, From 2013-01-01 |
| 2012-12-31 | -$46.28M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $53.81M | n/m | 2014-03-21, From 2011-01-01 |
| 2010-12-31 | -$38.46M | n/a | 2013-03-15, From 2010-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | -$38.55M | n/m |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $98.09M | -38.5% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $7.03M | n/m |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $52.60M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $99.65M | -29.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $59.01M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$575.00M | n/m |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $62.87M | -9.1% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$183.17M | n/m |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗